within Pharmacolibrary.Drugs.ATC.C;

model C09BA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 80 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,
    adminCount     = 1,
    Vd             = 0.0008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Perindopril and diuretics (such as indapamide) is a fixed-dose combination therapy used primarily for the treatment of hypertension and heart failure. Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that acts to lower blood pressure by inhibiting the renin-angiotensin-aldosterone system, while the diuretic component increases urinary excretion of sodium and water, further reducing blood pressure. This combination therapy is approved and widely used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic parameters for perindopril and indapamide combination in healthy adult subjects; parameters are estimated from publicly available sources for perindopril in combination with a thiazide-like diuretic (e.g., indapamide) as limited data for the fixed-dose combination are available.</p><h4>References</h4><ol><li><p>Macfadyen, RJ, et al., &amp; Reid, JL (1990). Perindopril. A review of its pharmacokinetics and clinical pharmacology. <i>Drugs</i> 39 Suppl 1 49–63. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199000391-00009&quot;>10.2165/00003495-199000391-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2407493/&quot;>https://pubmed.ncbi.nlm.nih.gov/2407493</a></p></li><li><p>Vandenburg, MJ, et al., &amp; Desche, P (1993). Digoxin pharmacokinetics and perindopril in heart failure patients. <i>Journal of clinical pharmacology</i> 33(2) 146–149. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1993.tb03935.x&quot;>10.1002/j.1552-4604.1993.tb03935.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8440763/&quot;>https://pubmed.ncbi.nlm.nih.gov/8440763</a></p></li><li><p>Ogawa, R, et al., &amp; Echizen, H (2014). Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). <i>Clinical pharmacokinetics</i> 53(12) 1083–1114. DOI:<a href=&quot;https://doi.org/10.1007/s40262-014-0189-3&quot;>10.1007/s40262-014-0189-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25248847/&quot;>https://pubmed.ncbi.nlm.nih.gov/25248847</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09BA04;
